A phase 1/2a, dose-escalation, safety, pharmacokinetic, and preliminary efficacy study of intraperitoneal administration of BC-819 (H19-DTA) in subjects with recurrent ovarian/peritoneal cancer.
about
A phase 1/2a, dose-escalation, safety, pharmacokinetic, and preliminary efficacy study of intraperitoneal administration of BC-819 (H19-DTA) in subjects with recurrent ovarian/peritoneal cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 February 2017
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A phase 1/2a, dose-escalation, ...... ent ovarian/peritoneal cancer.
@en
A phase 1/2a, dose-escalation, ...... ent ovarian/peritoneal cancer.
@nl
type
label
A phase 1/2a, dose-escalation, ...... ent ovarian/peritoneal cancer.
@en
A phase 1/2a, dose-escalation, ...... ent ovarian/peritoneal cancer.
@nl
prefLabel
A phase 1/2a, dose-escalation, ...... ent ovarian/peritoneal cancer.
@en
A phase 1/2a, dose-escalation, ...... ent ovarian/peritoneal cancer.
@nl
P2093
P2860
P1476
A phase 1/2a, dose-escalation, ...... ent ovarian/peritoneal cancer.
@en
P2093
Ami Fishman
Avraham Hochberg
Ayala Hubert
David Edelman
Michal Gilon
Ofer Lavie
Tally Levy
Yakir Segev
P2860
P2888
P304
P356
10.1007/S00404-017-4293-0
P577
2017-02-03T00:00:00Z